Lyell Immunopharma (NASDAQ:LYEL) Trading Up 14.7% - What's Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 14.7% during mid-day trading on Wednesday . The stock traded as high as $8.49 and last traded at $9.17. 46,019 shares traded hands during trading, a decline of 14% from the average session volume of 53,619 shares. The stock had previously closed at $7.99.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reissued a "neutral" rating and issued a $20.00 price objective on shares of Lyell Immunopharma in a research report on Wednesday, April 16th. Wall Street Zen raised Lyell Immunopharma to a "hold" rating in a research report on Friday.

Lyell Immunopharma Trading Up 11.3%

The stock has a market cap of $188.95 million, a PE ratio of -16.15 and a beta of -0.26. The business has a 50-day moving average price of $8.88 and a 200 day moving average price of $11.90.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Insider Activity at Lyell Immunopharma

In other Lyell Immunopharma news, Director Richard Klausner bought 7,900 shares of the firm's stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $94,800.00. Following the purchase, the director now directly owns 42,168 shares of the company's stock, valued at $506,016. The trade was a 23.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles W. Newton bought 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $11.20 per share, for a total transaction of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $112,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 38,432 shares of company stock worth $449,508. 25.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Decheng Capital LLC purchased a new position in shares of Lyell Immunopharma in the 4th quarter worth about $7,622,000. Foresite Capital Management V LLC purchased a new stake in Lyell Immunopharma during the 4th quarter valued at about $5,205,000. venBio Partners LLC purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $4,545,000. Almitas Capital LLC lifted its holdings in Lyell Immunopharma by 136.3% in the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Lyell Immunopharma by 716.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock worth $1,032,000 after acquiring an additional 1,414,746 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.